Patent number: 12201635
Abstract: A multi-target kinase inhibitor is shown in formula (I), in which R is selected from formula (a), formula (b), formula (c), formula (d), formula (e) and formula (f). The multi-target kinase inhibitor can effectively inhibit the enzymatic activities of RET, VEGFR3 and PDGFRA, and can effectively treat diseases that are regulated and controlled by multi-target kinases and are related to abnormal signal transduction pathways of the multi-target kinases, including cancers of breast, respiratory tract, brain, reproductive organ, digestive tract, urinary tract, eye, liver, skin, head and/or neck and distant metastatic cancers thereof, and lymphoma, sarcoma, leukemia and the like. The active ingredients of the pharmaceutical composition of the present invention comprise a multi-target kinase inhibitor, which accounts for 1-50 wt % of the composition.
Type:
Grant
Filed:
November 27, 2019
Date of Patent:
January 21, 2025
Assignees:
GUANGZHOU LIUSHUN BIOTECHNOLOGY CO., LTD., BEIJING BEIKEHUAXIA BIO-MEDICAL TECHNOLOGY CO., LTD.
Inventors:
Bing Liu, Jingsi Dai, Yan Wang, Xueqi Qian, Junjun Dong, Xihong Liu, Lianwu Deng, Shuang Xie, Daping Li, Nengan Chen, Jin Ma